AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Medicine intangible by Year
Medicine intangible — Baxdrostat (CinCor Pharma acquisition) ($M) ($M)
AstraZeneca Medicine intangible: $1,291M in FY2025, up 63.4% from a year earlier.
Latest, FY2025
1,291
Period ended Dec 31, 2025
Change on a year earlier
+63.4%
790 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Baxdrostat intangible asset acquired from CinCor Pharma, Inc. 1 | | 1,291 | | Not amortised |”
Reported in Form 20-F Note 10/11 — Significant Intangible Assets.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Medicine intangible — Baxdrostat (CinCor Pharma acquisition) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,291 | +63.4% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 790 | +1.3% | Form 20-F FY2024 Annual Report ↗ |
| FY2023 | Dec 31, 2023 | 780 | – | Form 20-F FY2023 Annual Report ↗ |
Cite this data
StockData. (2026). AstraZeneca Medicine intangible ($M), annual FY2023–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/intang-med-baxdrostat
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.